title: Acid cysteine proteinase inhibitor in cutaneous lymphocytic infiltrates.
abstract: Acid cysteine proteinase inhibitor (ACPI, cystatin A) is normally present in squamous epithelium and dendritic cells of lymphoid follicles. Its expression is altered both in proliferative and malignant squamous epithelium and in neoplastic lymphoid follicles. The expression of ACPI in the lymphoid infiltrates of cutaneous psuedolymphomas and B-cell lymphomas was studied. Eighteen pseudolymphomas from 15 patients were divided into three groups according to the proportion of B and T lymphocytes. The B-cell-type lesions with well-developed follicles and germinal centers showed a pronounced ACPI expression in dendritic cells. Varying amounts of ACPI-positive cells were present in the mixed B- and T-cell-type and also in the T-cell-type lesions. The labeled cell population was distinct from the factor XIIIa-positive dermal dendrocytes, S-100-positive histiocytes, and HAM 56-positive histiocytes. Malignant lymphomas contained a few haphazardly arranged ACPI-positive cells with short dendrites and granular cytoplasm. It was concluded that follicular dendritic cells can be reliably labeled with ACPI antiserum in cutaneous pseudolymphomas. The structure and distribution of ACPI-containing cells in malignant cutaneous B-cell lymphomas is altered when compared with pseudolymphomas.
authors.affiliation: Department of Pathology, University of Turku, Finland.
authors.forename: H J
authors.initials: HJ
authors.lastname: Aho
authors.forename: W
authors.initials: W
authors.lastname: Ping
authors.forename: K O
authors.initials: KO
authors.lastname: Söderström
authors.forename: A
authors.initials: A
authors.lastname: Rinne
authors.forename: R
authors.initials: R
authors.lastname: Rinne
authors.forename: V K
authors.initials: VK
authors.lastname: Hopsu-Havu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D000911:Antibodies, Monoclonal; D001402:B-Lymphocytes / Q000473:pathology; D002648:Child; D015891:Cystatins / Q000032:analysis* / Q000235:genetics; D015853:Cysteine Proteinase Inhibitors / Q000032:analysis* / Q000235:genetics; D003593:Cytoplasm / Q000648:ultrastructure; D003594:Cytoplasmic Granules / Q000648:ultrastructure; D003713:Dendritic Cells / Q000473:pathology; D004848:Epithelium / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006644:Histiocytes / Q000473:pathology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D009418:S100 Proteins / Q000032:analysis; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology*; D013601:T-Lymphocytes / Q000473:pathology; D011503:Transglutaminases / Q000032:analysis
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D015891:Cystatins; D015853:Cysteine Proteinase Inhibitors; C096893:HAM-56 antibody; D009418:S100 Proteins; D011503:Transglutaminases